Electrochemiluminescence Immunoassay (ECLIA): Definition and Clinical Applications
Electrochemiluminescence immunoassay (ECLIA) is an advanced immunoassay technology that detects antigen-antibody reactions through light emission triggered by electrochemical reactions, offering superior sensitivity compared to traditional enzyme immunoassays and enabling automated, high-throughput clinical diagnostics across multiple medical specialties.
Technical Principles
ECLIA represents a significant advancement over conventional enzyme-linked immunosorbent assays (ELISAs) by utilizing electrochemical stimulation to generate luminescent signals 1. The technology combines the specificity of immunological reactions with the sensitivity of electrochemiluminescence detection, allowing measurement of analytes at very low concentrations 2. The assay format typically involves magnetic bead separation and photomultiplier tube (PMT) detection systems to achieve high sensitivity and accuracy 3.
Key Clinical Applications
Hepatitis C Diagnosis
ECLIA has become increasingly utilized for detecting anti-HCV antibodies, as it detects antigen-antibody reactions more sensitively compared to third-generation EIA 1. The enhanced sensitivity is particularly valuable during the early seroconversion period when antibody levels may be low 1.
Therapeutic Drug Monitoring
In inflammatory bowel disease management, ECLIA is one of the most commonly used assay formats for measuring anti-tumor necrosis factor (anti-TNF) drug concentrations and anti-drug antibodies 2. However, caution is warranted when extrapolating therapeutic cutoff values across different assay platforms, especially for adalimumab, as ECLIA results may not be directly comparable to ELISA or homogenous mobility shift assay (HMSA) results 2.
Alzheimer's Disease Biomarkers
The Lumipulse G system, which runs electrochemiluminescence immunoassays, has expanded into blood biomarker testing for Alzheimer's disease 4. Assays are now available for plasma amyloid-beta peptides, neurofilament light chain (NfL), phosphorylated tau-181 (p-tau181), and phosphorylated tau-217 (p-tau217) 4. This represents a significant advancement given that blood AD biomarkers often have smaller effect sizes than CSF biomarkers due to peripheral tissue dilution 4.
COVID-19 Antigen Detection
The fully-automated Roche Elecsys SARS-CoV-2 antigen ECLIA has demonstrated pooled diagnostic specificity of 0.99 and sensitivity of 0.68 in nasopharyngeal samples 5. In samples with high viral load (cycle threshold values <28-30), the diagnostic sensitivity increases to 0.95, making it reliable for mass screening and supporting shortened isolation strategies 5.
Endocrine Disorders
ECLIA has proven effective for measuring late-night salivary cortisol in screening for Cushing's syndrome 6. Using a cut-off value of 9.4 nmol/L, ECLIA achieved sensitivity of 84.4% and specificity of 92.3% in obese and overweight patients, with diagnostic performance comparable to the low-dose dexamethasone suppression test 6. Due to its automation and comparable diagnostic performance, ECLIA is preferable as a first-line screening test 6.
Oncology Applications
ECLIA has demonstrated superior diagnostic performance for hepatocellular carcinoma detection using IgM-free apoptosis inhibitor of macrophage (AIM) as a biomarker 7. The area under the receiver operating curve for IgM-free AIM was greater than conventional HCC biomarkers (alpha-fetoprotein or des-γ-carboxy prothrombin) regardless of cancer stage 7. Additionally, ECLIA targeting serum HER2 extracellular domain enables ultrasensitive detection (detection limit 11 pg/mL) for breast cancer evaluation, with strong correlation to tissue HER2 expression 8.
Advantages Over Traditional Methods
ECLIA offers several key advantages: automation capability for high-throughput testing, enhanced sensitivity with lower detection limits (12-15 IU/mL for some applications), broad dynamic range, and reduced turnaround time compared to conventional ELISAs 1, 3. The technology achieves high signal-to-noise ratios and excellent precision, meeting clinical requirements for detection capacity and throughput 3.
Important Considerations
When interpreting ECLIA results, clinicians should recognize that different assay platforms may yield varying results for the same analyte 2. Platform-specific reference ranges and cutoff values must be established and validated, as thresholds cannot be directly transferred between ELISA and ECLIA systems 9. External quality assessment programs have demonstrated variability in semiquantitative classification between platforms, emphasizing the need for laboratory-specific validation 9.
The technology requires appropriate specimen handling, with specific requirements for sample volume, storage conditions, and processing procedures to ensure valid results 4. Quality control measures including accuracy, precision, specificity, and robustness testing are essential for clinical implementation 10.